Trial on Early Stage Lung Cancer Chemotherapy
Author Information
Author(s): Michael Kreuter, Johan Vansteenkiste, Frank Griesinger, Hans Hoffmann, Hendrik Dienemann, Paul De Leyn, Michael Thomas
Primary Institution: Thoraxklinik at the University of Heidelberg
Hypothesis
Reduced toxicities might improve the feasibility of drug delivery, compliance and the convenience of treatment for the patient and perhaps survival.
Conclusion
The study aims to evaluate the clinical feasibility of two chemotherapy regimens for early stage non-small cell lung cancer.
Supporting Evidence
- Adjuvant chemotherapy has been shown to be beneficial for early stage non-small cell lung cancer.
- Toxicity and inadequate dose delivery have been critical issues in previous chemotherapy trials.
- Pemetrexed shows clear activity in non-small cell lung cancer with lower toxicity rates.
Takeaway
This study is testing two types of chemotherapy to see which one is easier for patients to handle after lung cancer surgery.
Methodology
This is a prospective, multi-center, open label randomized phase II study comparing two chemotherapy regimens in patients with early stage non-small cell lung cancer after surgery.
Potential Biases
Potential biases may arise from the open-label design and patient selection criteria.
Limitations
The study may not account for all variables affecting patient outcomes, and the sample size may limit the generalizability of the findings.
Participant Demographics
Patients with pathologically confirmed non-small cell lung cancer, stage IB, IIA, IIB, T3N1, aged 18-75.
Statistical Information
P-Value
0.08
Confidence Interval
95% CI 0.17–0.68
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website